-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Maintains Buy on Revolution Medicines, Raises Price Target to $240

Benzinga·08/06/2026 10:09:42
Listen to the news
Needham analyst Ami Fadia maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $236 to $240.